InsightsRx  Erstellt neuen Artikel
2 w ·übersetzen

A Superior Alternative: P-CABs vs. PPIs | #vonoprazan Fumarate Api Market

A Superior Alternative: P-CABs vs. PPIs

A Superior Alternative: P-CABs vs. PPIs

Valued at approximately USD 1.25 billion in 2024, the market is on a trajectory to reach an estimated USD 4.83 billion by 2034, reflecting a strong compound annual growth rate (CAGR) of 14.51% over the forecast period